A Phase I Study of Oral UE2343 in Healthy Subjects

Overview

A randomised, double-blind, placebo-controlled, phase I study in healthy subjects. Safety, pharmacokinetic and pharmacodynamic data will be collected.

Full Title of Study: “A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 2013

Interventions

  • Drug: UE2343
    • Oral capsule
  • Drug: Placebo
    • Oral capsule

Arms, Groups and Cohorts

  • Active Comparator: UE2343
    • Oral capsule
  • Placebo Comparator: Placebo
    • Oral capsule

Clinical Trial Outcome Measures

Primary Measures

  • Safety and tolerability of UE2343 in healthy male/female subjects
    • Time Frame: At each dose
    • Days 1-2 at each dose: 12 lead ECG Vital signs Symptom led clinical assessment (day 1 only) Routine laboratory assessments Days 3-6 at each dose: 12 lead ECG Vital signs Routine laboratory assessments Day 10 at each dose: 12 lead ECG Vital signs Routine laboratory assessments Physical examination Pregnancy test

Secondary Measures

  • Pharmacokinetic parameters of UE2343 and pharmacodynamic exposure
    • Time Frame: At each dose
    • Days 1-2 at each dose: Blood and urine samples for measurement of UE2343 Blood samples for adrenal androgens Blood samples for ACTH and cortisol Urine samples for urinary free steroids Days 3-6 at each dose: Blood and urine samples for measurement of UE2343 Blood samples for adrenal androgens Blood samples for ACTH and cortisol Urine samples for urinary free steroids

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male and female subjects between 18 and 65 years of age (inclusive).
  • Female subject is postmenopausal or surgically sterilized or had a hysterectomy.
  • Female subject with negative pregnancy test.
  • Male subjects willing to use an effective method of contraception, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from Day 1 until 3 months afterwards.
  • Subject with a Body Mass Index (BMI) of 18-30 kg/m2. Body Mass Index = Body weight (kg) / [Height (m)]2.
  • Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values or results suggesting an infectious or other systemic disorder. The parameters to be measured will include those shown in Appendix 2. The Simbec normal ranges are shown in Appendix 3.
  • Subject with a negative urinary drugs of abuse screen (Appendix 2) (N.B. a positive alcohol result may be repeated at the discretion of the Investigator).
  • Subject with negative HIV and Hepatitis B and C results.
  • Subject with no clinically significant abnormalities in 12-lead electrocardiogram (ECG).
  • no clinically significant abnormalities in vital signs.
  • willing and able to comply with the requirements of the protocol.
  • satisfy a medical examiner about fitness to participate in the study.
  • provide written informed consent to participate in the study.
  • Smokers are eligible to participate in the study.

Exclusion Criteria

  • Relevant abnormality in medical history or on examination, including history of dementia, or other psychiatric, neurological, immunological, respiratory or cardiovascular disorder. Particularly exclude subjects with signs of peripheral neuropathy. Abnormal laboratory findings suggesting the presence of a systematic disorder.
  • Participation in a clinical study of an unlicensed drug in the previous 4 months, or a marketed drug study within the previous 3 months. (N.B. washout period between trials defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
  • Known allergies, including allergy to chemicals like and excipients associated with UE2343.
  • Recent or clinically significant history of drug or alcohol abuse.
  • Blood donation greater than 500 ml in the previous 3 months.
  • Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
  • Receipt of regular prescribed medication within 7 days of the first study day and / or receipt of vitamins, minerals, herbal remedies and nutritional supplements within 7 days of the first study day. Subjects taking long lasting drugs more than 7 days before the study may be excluded at the physician's discretion. Inclusion of subjects who have taken over the counter drugs during this period will be reviewed on a case-by-case basis in relation to the safety aspects and objectives of this study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Edinburgh
  • Collaborator
    • Wellcome Trust
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Brian R Walker, BSc MBChB MD, Principal Investigator, University of Edinburgh

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.